Results 31 to 40 of about 280,719 (209)

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates

Emerging Microbes and Infections, 2021
COVID-19 vaccines emerging from different platforms differ in efficacy, duration of protection, and side effects. To maximize the benefits of vaccination, we explored the utility of employing a heterologous prime-boost strategy in which different ...
Qian He, Qunying Mao, Chaoqiang An, Jialu Zhang, Fan Gao, Lian-lian Bian, Changgui Li, Zhenglun Liang, Miao Xu, Junzhi Wang   +9 more
semanticscholar   +1 more source

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies

bioRxiv, 2021
The massive and rapid transmission of SARS-CoV-2 has led to the emergence of several viral variants of concern (VOCs), with the most recent one, B.1.1.529 (Omicron), which accumulated a large number of spike mutations, raising the specter that this newly
Xun Wang, Xiaoyu Zhao, Jieyu Song, Jing Wu, Yuqi Zhu, Minghui Li, Yuchen Cui, Yanjia Chen, Lu Yang, Jun Liu, Huanzhang Zhu, Shibo Jiang, Pengfei Wang   +12 more
semanticscholar   +1 more source

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study

The Lancet Regional Health - Europe, 2021
Summary Background The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown. Methods From individuals vaccinated with two doses against Covid-19 in Sweden until July 5, 2021 (N=3,445,061), we ...
P. Nordström, M. Ballin, A. Nordström
semanticscholar   +1 more source

Heterologous Antilymphocyte Globulin [PDF]

New England Journal of Medicine, 1968
THE immunosuppressive properties of heterologous antilymphocyte serum and its globulin derivative have been well known since 1961, when it was reported that a variety of immunologic responses could...
openaire   +2 more sources

Aerosol Inhalation of Chimpanzee Adenovirus Vectors (ChAd68) Expressing Ancestral or Omicron BA.1 Stabilized Pre–Fusion Spike Glycoproteins Protects Non–Human Primates against SARS-CoV-2 Infection

Vaccines, 2023
Current COVID-19 vaccines are effective countermeasures to control the SARS-CoV-2 virus pandemic by inducing systemic immune responses through intramuscular injection.
Shen Wang, Mian Qin, Long Xu, Ting Mu, Ping Zhao, Bing Sun, Yue Wu, Lingli Song, Han Wu, Weicheng Wang, Xingwen Liu, Yanyan Li, Fengmei Yang, Ke Xu, Zhanlong He, Michel Klein, Ke Wu   +16 more
doaj   +1 more source

Influenza D Virus of New Phylogenetic Lineage, Japan

Emerging Infectious Diseases, 2020
Influenza D virus (IDV) can potentially cause respiratory diseases in livestock. We isolated a new IDV strain from diseased cattle in Japan; this strain is phylogenetically and antigenically distinguished from the previously described IDVs.
Shin Murakami, Ryota Sato, Hiroho Ishida, Misa Katayama, Akiko Takenaka-Uema, Taisuke Horimoto   +5 more
doaj   +1 more source

Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants

Science, 2021
Description Immune imprinting For severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), immune responses to heterologous variants are influenced by a person’s infection history.
C. Reynolds, J. Gibbons, C. Pade, K. Lin, Diana Mūnoz Sandoval, F. Pieper, D. Butler, Siyi Liu, A. Otter, G. Joy, K. Menacho, M. Fontana, A. Smit, B. Kele, T. Cutino-Moguel, M. Maini, M. Noursadeghi, T. Brooks, A. Semper, C. Manisty, T. Treibel, J. Moon, Á. McKnight, D. Altmann, R. Boyton   +24 more
semanticscholar   +1 more source

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

Nature Communications, 2021
Several vaccines have demonstrated efficacy against SARS-CoV-2 mediated disease, yet there is limited data on the immune response induced by heterologous vaccination regimens using alternate vaccine modalities.
Alexandra J. Spencer, P. Mckay, Sandra Belij-Rammerstorfer, M. Ulaszewska, Cameron Bissett, Kai Hu, K. Samnuan, A. Blakney, D. Wright, H. Sharpe, Ciarán Gilbride, Adam Truby, E. Allen, S. Gilbert, R. Shattock, T. Lambe   +15 more
semanticscholar   +1 more source

Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients

JAMA Internal Medicine, 2021
Key Points Question Does a heterologous SARS-CoV-2 vaccination strategy with the vector vaccine Ad26COVS1 result in a higher rate of antibody response compared with a homologous third dose of mRNA vaccine (mRNA-1273 or BNT162b2) in kidney transplant ...
R. Reindl-Schwaighofer, A. Heinzel, M. Mayrdorfer, Rhea Jabbour, T. Hofbauer, A. Merrelaar, M. Eder, Florina Regele, K. Doberer, Paul Spechtl, C. Aschauer, M. Koblischke, C. Paschen, F. Eskandary, Karin Hu, Barbara Öhler, Arshdeep Bhandal, Sabine Kleibenböck, Rahel Jagoditsch, Bianca Reiskopf, F. Heger, G. Bond, G. Böhmig, R. Strassl, L. Weseslindtner, A. Indra, J. Aberle, Michael Binder, R. Oberbauer   +28 more
semanticscholar   +1 more source

Past Life and Future Effects—How Heterologous Infections Alter Immunity to Influenza Viruses

Frontiers in Immunology, 2018
Influenza virus frequently mutates due to its error-prone polymerase. This feature contributes to influenza virus’s ability to evade pre-existing immunity, leading to annual epidemics and periodic pandemics.
Aisha Souquette, Paul G. Thomas
doaj   +1 more source